Atrion Corporation Intrinsic Value – ATRION CORPORATION Reports Q4 FY2022 Earnings Results Ending December 31, 2022.
March 21, 2023
Earnings Overview
ATRION CORPORATION ($NASDAQ:ATRI) reported its financial results for the fourth quarter of FY2022, which ended December 31, 2022, on February 27, 2023. The company’s total revenue for the period was USD 8.3 million, a 2.3% increase from the previous year. Net income for the quarter was USD 42.9 million, representing a 6.4% increase from the same quarter in the previous year.
Share Price
On Monday, ATRION CORPORATION reported their fourth quarter earnings results ending December 31, 2022. The stock opened at $652.6 and closed at the same price, representing a 4.4% decline from its previous closing price of $682.8. The company stated that they had seen a decline in revenues due to the pandemic, but that they had managed to make up some of this loss with cost-cutting measures.
Despite the lower than expected fourth quarter results, ATRION CORPORATION announced plans to expand their operations and invest in new technologies that are expected to increase earnings in the coming quarters. The company also stated that they have seen growth in their customer base, which is expected to drive more revenue in the coming months. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atrion Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 183.51 | 35.01 | 19.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atrion Corporation. More…
| Operations | Investing | Financing |
| 28.79 | -15.28 | -41.04 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atrion Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 264.71 | 25.17 | 136.03 |
Key Ratios Snapshot
Some of the financial key ratios for Atrion Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.8% | -0.7% | 21.6% |
| FCF Margin | ROE | ROA |
| -2.7% | 10.2% | 9.4% |
Analysis – Atrion Corporation Intrinsic Value
At GoodWhale, we recently conducted an analysis of ATRION CORPORATION‘s wellbeing. After evaluating the company’s financials and other indicators, we were able to arrive at an estimated intrinsic value of ATRION CORPORATION share of around $751.7 with our proprietary Valuation Line. Currently, ATRION CORPORATION stock is being traded at a price of $652.6. This is a price that is a fair market price, but that is also undervalued by 13.2%. This presents an opportunity for investors to potentially reap rewards from buying the stock at its current price. More…
Peers
In the medical device industry, Atrion Corp competes against LeMaitre Vascular Inc, AtriCure Inc, and Nova Eye Medical Ltd. All four companies offer products that are used to treat cardiovascular diseases. Atrion has a history of innovation, which has allowed it to become a leader in the industry. The company’s competitors have also been successful in their own right, and each offers a unique product portfolio.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that develops, manufactures, and markets vascular devices for the treatment of peripheral vascular disease. Its products are used by vascular surgeons and interventionalists for arterial and venous vessel reconstruction. The company’s products include stents, balloons, and other devices. It has operations in the United States, Europe, Canada, Australia, and Asia.
– AtriCure Inc ($NASDAQ:ATRC)
AtriCure, Inc. is a leading manufacturer of medical devices that provide surgical ablation solutions for the treatment of atrial fibrillation and other cardiac conditions. The company has a market cap of 2.14B as of 2022 and a Return on Equity of -7.05%. AtriCure’s products are sold in over 50 countries and are backed by a strong clinical evidence base. The company’s mission is to improve the lives of patients by providing minimally invasive solutions that treat cardiac conditions with fewer complications and shorter hospital stays.
– Nova Eye Medical Ltd ($ASX:EYE)
Nova Eye Medical Ltd is a publicly traded company that provides ophthalmic products and services. As of 2022, the company had a market capitalization of 40.84 million and a return on equity of -18.79%. Nova Eye Medical Ltd offers a variety of ophthalmic products and services, including cataract surgery, refractive surgery, ocular implants, and more. The company has a presence in both the United States and Canada.
Summary
At the end of FY2022 Q4, ATRION CORPORATION had total revenue of USD 8.3 million and net income of USD 42.9 million, showing an increase of 2.3% and 6.4% respectively from the year prior. Despite this positive news, the company’s stock price dropped on the same day, suggesting that investors were not impressed with the results. Going forward, investors should keep a close eye on ATRION CORPORATION to gauge how the company continues to perform and if its financial results will be able to meet the expectations of the market.
